Gain-framed Messages and NRT for Lung Cancer Screening Patients
This research is a randomized smoking cessation trial conducted within and specifically personalized for lung cancer screening patients presenting to a lung screening clinic. Novel tobacco treatments for this population are critically needed, given the growing population of lung screening patients, which will grow dramatically now that lung screening is an approved CMS benefit. In the proposed study, we will test a gain-framed messaging intervention specifically designed for lung screening patients (vs. unframed messaging), as well as evaluating NRT sampling (vs. no medication) at 2 study sites. Our project is designed to be translational (in that it can be transferable from our controlled efficacy study to other lung screening programs).
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jan 14, 2025 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Medical University of South Carolina
- Interventions being studied
- Behavioral: Gain-framed messaging; Combination Product: Unframed messaging materials
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
1. 50 years or older 2. at least a 20-pack year history of smoking 3. current smoker (defined as any smoking in the past 30 days) 4. willing to be randomized 5. English speaking
1. unstable psychiatric/medical conditions such as suicidal ideation, acute psychosis, severe alcohol dependence, or dementia, 2. known allergy to adhesives 3. being in the immediate (within 2 weeks) post myocardial infarction period 4. serious arrhythmias 5. unstable angina pectoris 6. hemodynamically or electrically unstable. 7. current participation in another tobacco treatment program (e.g., using medication from a primary care doctor, Quitline, etc.)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Yale Cancer CenterNew Haven, Connecticut
- Medical University of South CarolinaCharleston, South Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 14, 2025. Always confirm current availability with the study team.